Roivant Sciences Ltd. (NASDAQ:ROIV) Shares Bought by Thrivent Financial for Lutherans

Thrivent Financial for Lutherans boosted its position in shares of Roivant Sciences Ltd. (NASDAQ:ROIV) by 119.9% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 186,051 shares of the company’s stock after purchasing an additional 101,437 shares during the period. Thrivent Financial for Lutherans’ holdings in Roivant Sciences were worth $1,966,000 at the end of the most recent reporting period.

Other large investors have also added to or reduced their stakes in the company. nVerses Capital LLC acquired a new stake in Roivant Sciences during the 2nd quarter valued at $34,000. Acadian Asset Management LLC acquired a new stake in Roivant Sciences during the 1st quarter valued at $72,000. Fifth Third Wealth Advisors LLC acquired a new stake in Roivant Sciences during the 2nd quarter valued at $101,000. ORG Partners LLC acquired a new stake in Roivant Sciences during the 2nd quarter valued at $106,000. Finally, Capstone Investment Advisors LLC acquired a new stake in Roivant Sciences during the 4th quarter valued at $170,000. 64.76% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on ROIV shares. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Roivant Sciences in a report on Thursday, September 19th. HC Wainwright reiterated a “buy” rating and set a $18.00 price objective on shares of Roivant Sciences in a research note on Thursday, September 19th. Bank of America increased their price objective on shares of Roivant Sciences from $12.00 to $12.50 and gave the company a “neutral” rating in a research note on Wednesday, September 11th. Finally, Piper Sandler increased their price objective on shares of Roivant Sciences from $20.00 to $22.00 and gave the company an “overweight” rating in a research note on Wednesday, July 10th. One investment analyst has rated the stock with a hold rating and nine have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $17.39.

Roivant Sciences Trading Down 1.5 %

Roivant Sciences stock opened at $11.37 on Wednesday. The firm’s 50-day moving average is $11.51 and its 200-day moving average is $11.10. The company has a debt-to-equity ratio of 0.05, a quick ratio of 27.91 and a current ratio of 27.91. Roivant Sciences Ltd. has a 1 year low of $8.24 and a 1 year high of $13.06. The company has a market cap of $8.40 billion, a P/E ratio of 2.25 and a beta of 1.25.

Roivant Sciences (NASDAQ:ROIV) last posted its quarterly earnings results on Thursday, August 8th. The company reported $0.12 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.21) by $0.33. The company had revenue of $55.10 million for the quarter, compared to the consensus estimate of $30.72 million. Roivant Sciences had a net margin of 2,991.75% and a negative return on equity of 17.23%. The company’s revenue for the quarter was up 155.1% on a year-over-year basis. During the same period last year, the firm posted ($0.38) EPS. On average, equities analysts expect that Roivant Sciences Ltd. will post -1.14 earnings per share for the current year.

Insider Activity at Roivant Sciences

In related news, CAO Rakhi Kumar sold 250,000 shares of Roivant Sciences stock in a transaction dated Monday, September 23rd. The shares were sold at an average price of $11.89, for a total value of $2,972,500.00. Following the sale, the chief accounting officer now directly owns 209,322 shares in the company, valued at approximately $2,488,838.58. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. In related news, CAO Rakhi Kumar sold 250,000 shares of Roivant Sciences stock in a transaction dated Monday, September 23rd. The shares were sold at an average price of $11.89, for a total value of $2,972,500.00. Following the sale, the chief accounting officer now directly owns 209,322 shares in the company, valued at approximately $2,488,838.58. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CEO Matthew Gline sold 1,983,257 shares of Roivant Sciences stock in a transaction dated Monday, September 23rd. The shares were sold at an average price of $11.79, for a total transaction of $23,382,600.03. Following the completion of the sale, the chief executive officer now owns 17,870,543 shares in the company, valued at $210,693,701.97. The disclosure for this sale can be found here. Insiders have sold a total of 3,477,309 shares of company stock worth $40,986,184 in the last ninety days. 4.60% of the stock is owned by insiders.

Roivant Sciences Company Profile

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.